Sankyo Parke Davis Will Double Sales Force To Market GelTex Cholestagel
Executive Summary
Sankyo Parke Davis intends to double its sales force to support the marketing and sales of GelTex' cholesterol reduction agent Cholestagel (colesevelam).
You may also be interested in...
Sankyo/Forest Benicar Launch Set For May; Seventh Angiotensin II Inhibitor
Sankyo and Forest will launch the angiotensin II inhibitorBenicar (olmesartan) with a 1,200-person sales force
Sankyo/Forest Benicar Launch Set For May; Seventh Angiotensin II Inhibitor
Sankyo and Forest will launch the angiotensin II inhibitorBenicar (olmesartan) with a 1,200-person sales force
Genzyme Sees Renagel Clinical Data Driving Sales After Purchase Of GelTex
Renagel sales growth will be driven by results from cardiac calcification and morbidity and mortality trials, Genzyme Chairman Henri Termeer indicated during a Sept. 11 conference call announcing Genzyme's $1 bil. acquisition of GelTex.